Ionetix Corp / DE /

S-1/A amended

229,091 shares

Ionetix Corp's S-1/A filing updates financial disclosures, emphasizing revenue recognition policies, accounts receivable allowances, and lease obligations. Key details include a $2.1M allowance for credit losses on accounts receivable, a $1.7M allowance for a non-repaid loan receivable, and inventory reclassification as non-current due to cyclotron system capitalization. The filing highlights revenue from diagnostic drugs, cyclotron sales, and consulting services, with significant customer concentration risks. It also addresses lease liabilities, asset retirement obligations, and fair value adjustments for SAFEs and derivatives.

S-1 filed

Ionetix Corp, a Delaware-incorporated company, develops superconducting cyclotron technology to produce medical and industrial isotopes. The company's revenue comes from diagnostic drug sales, cyclotron system sales, and consulting services. Recent financial results show declining revenue, with a 59% drop in Q1 2026 compared to Q1 2025, primarily due to reduced cyclotron system sales. The company has incurred significant losses, with a net loss of $6.9 million in Q1 2026 and $39.7 million for the full year 2025. Key challenges include revenue volatility tied to real-time demand, reliance on limited production capacity, and financial risks from convertible notes and SAFEs.